Linked Life Data

10839289

Source:http://linkedlifedata.com/resource/pubmed/id/10839289

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10839289rdf:typepubmed:Citationlld:pubmed
pubmed-article:10839289lifeskim:mentionsumls-concept:C0346647lld:lifeskim
pubmed-article:10839289lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:10839289lifeskim:mentionsumls-concept:C0231220lld:lifeskim
pubmed-article:10839289lifeskim:mentionsumls-concept:C0045093lld:lifeskim
pubmed-article:10839289lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:10839289lifeskim:mentionsumls-concept:C0444889lld:lifeskim
pubmed-article:10839289lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:10839289lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:10839289lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:10839289pubmed:issue11lld:pubmed
pubmed-article:10839289pubmed:dateCreated2000-6-13lld:pubmed
pubmed-article:10839289pubmed:abstractTextGemcitabine and 5-fluorouracil are the only two compounds with reproducible activity against advanced pancreatic cancer (APC). We have evaluated a novel combination of gemcitabine and 5-fluorouracil on the clinical benefit response (CBR) end point. Eleven consecutive patients with symptomatic APC were entered in a two-stage phase II trial. Gemcitabine was administered by intravenous (i.v.) bolus injection at the dose of 1,000 mg m(-2) on days 1, 8, 15 and 5-fluorouracil 500 mg m(-2) was given by continuous i.v. infusion on days 1-5. Treatment was repeated every 28 days. A CBR was achieved in 7/11 patients. The mean time to loss of CBR was 26.5 weeks (range 14-18, median 22). Toxicity was mild and no APC patient experienced WHO grade 3 toxicity. The gemcitabine/5-fluorouracil combination is well tolerated and produces a symptomatic relief in the majority of APC patients.lld:pubmed
pubmed-article:10839289pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10839289pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10839289pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10839289pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10839289pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10839289pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10839289pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10839289pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10839289pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10839289pubmed:languageenglld:pubmed
pubmed-article:10839289pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10839289pubmed:citationSubsetIMlld:pubmed
pubmed-article:10839289pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10839289pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10839289pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10839289pubmed:statusMEDLINElld:pubmed
pubmed-article:10839289pubmed:monthJunlld:pubmed
pubmed-article:10839289pubmed:issn0007-0920lld:pubmed
pubmed-article:10839289pubmed:authorpubmed-author:LibroiaAAlld:pubmed
pubmed-article:10839289pubmed:authorpubmed-author:BiancoA RARlld:pubmed
pubmed-article:10839289pubmed:authorpubmed-author:DamianoVVlld:pubmed
pubmed-article:10839289pubmed:authorpubmed-author:TagliaferroVVlld:pubmed
pubmed-article:10839289pubmed:authorpubmed-author:MatanoEElld:pubmed
pubmed-article:10839289pubmed:authorpubmed-author:De LorenzoSSlld:pubmed
pubmed-article:10839289pubmed:authorpubmed-author:FabbrociniAAlld:pubmed
pubmed-article:10839289pubmed:issnTypePrintlld:pubmed
pubmed-article:10839289pubmed:volume82lld:pubmed
pubmed-article:10839289pubmed:ownerNLMlld:pubmed
pubmed-article:10839289pubmed:authorsCompleteYlld:pubmed
pubmed-article:10839289pubmed:pagination1772-5lld:pubmed
pubmed-article:10839289pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:10839289pubmed:meshHeadingpubmed-meshheading:10839289...lld:pubmed
pubmed-article:10839289pubmed:meshHeadingpubmed-meshheading:10839289...lld:pubmed
pubmed-article:10839289pubmed:meshHeadingpubmed-meshheading:10839289...lld:pubmed
pubmed-article:10839289pubmed:meshHeadingpubmed-meshheading:10839289...lld:pubmed
pubmed-article:10839289pubmed:meshHeadingpubmed-meshheading:10839289...lld:pubmed
pubmed-article:10839289pubmed:meshHeadingpubmed-meshheading:10839289...lld:pubmed
pubmed-article:10839289pubmed:meshHeadingpubmed-meshheading:10839289...lld:pubmed
pubmed-article:10839289pubmed:meshHeadingpubmed-meshheading:10839289...lld:pubmed
pubmed-article:10839289pubmed:meshHeadingpubmed-meshheading:10839289...lld:pubmed
pubmed-article:10839289pubmed:meshHeadingpubmed-meshheading:10839289...lld:pubmed
pubmed-article:10839289pubmed:meshHeadingpubmed-meshheading:10839289...lld:pubmed
pubmed-article:10839289pubmed:meshHeadingpubmed-meshheading:10839289...lld:pubmed
pubmed-article:10839289pubmed:year2000lld:pubmed
pubmed-article:10839289pubmed:articleTitleGemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study.lld:pubmed
pubmed-article:10839289pubmed:affiliationCattedra di Oncologia Medica, Dipartimento di Endocrinologia ed Oncologia Molecolare a Clinica, Facoltà di Medicina e Chirurgia, Università Federico II, Napoli, Italy.lld:pubmed
pubmed-article:10839289pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10839289pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:10839289pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10839289lld:pubmed